Termination of tyrphostin AG1478 application results in different recovery of EGF receptor tyrosine residues 1045 and 1173 phosphorylation in A431 cells

Cell Biology International

Volumn 34, Issue 1, 2010, Pages 81-87

  Kondratov, Kirill A ^a   Chernorudskiy, Alexander L ^a,b   Amosova, Alina P ^a   Kornilova, Elena S ^a  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b PRIVOLZHSKY RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

A431 cell; AG1478; Epidermal growth factor receptor (EGFR); Extracellular signal regulated kinase 1 2 (ERK1 2); Tyrosine phosphorylation; Ubiquitination

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; TYROSINE; MITOGEN ACTIVATED PROTEIN KINASE 3; TYRPHOSTIN;

ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; ENDOCYTOSIS; ENDOSOME; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYSOSOME; MITOGENESIS; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UBIQUITINATION; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; ENDOCYTOSIS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYROSINE; TYRPHOSTINS; UBIQUITINATION;

EID: 77951934893     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20090159     Document Type: Article

References (32)

1. Babst M. A protein's final ESCRT. Traffic 2005;6:2-9.
2. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
3. Bowtell DD, Langdon WY. The protein product of the c-cbl oncogene rapidly complexes with the EGF receptor and is tyrosine phosphorylated following EGF stimulation. Oncogene 1995;11:1561-7.
4. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11:397-405.
5. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
6. Cohen S, Fava RA. Internalization of functional epidermal growth factor: receptor/kinase complexes in A-431 cells. J Biol Chem 1985;260:12351-8.
7. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984;311:483-5.
8. Ellis AG, Nice EC, Weinstock J, Levitzki A, Burgess AW, Webster LK. High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. J Chromatogr B Biomed Sci Appl. 2001;754:193-9.
9. Ellis AG, Doherty MM, Walker F, Weinstock J, Nerrie M, Vitali A et al. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 2006;71:1422-34.
10. Gan HK, Walker F, Burgess AW, Rigopoulos A, Scott AM, Johns TG. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem 2007;282:2840-50.
11. Gosh S, Liu XP, Zheng Y, Uckun FM. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Curr Cancer Drug Targets 2001;1:129-40.
12. Grøvdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004;300:388-95.
13. Guo L, Kozlosky CJ, Ericsson LH, Daniel TO, Cerretti DP, Johnson RS. Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor. J Am Soc Mass Spectrom 2003;14:1022-31.
14. Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 1996;56:3859-61.
15. Honegger AM, Szapary D, Schmidt A, Lyall R, Van Obberghen E, Dull TJ et al. A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis. Mol Cell Biol 1987;7:4568-71.
16. Jaramillo ML, Leon Z, Grothe S, Paul-Roc B, Abulrob A, O'Connor McCourt M. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 2006;312:2778-90.
17. Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003;63:1-5.
18. Kornilova E, Sorkina T, Beguinot L, Sorkin A. Lysosomal targeting of epidermal growth factor receptors via a kinase-dependent pathway is mediated by the receptor carboxyl-terminal residues. J Biol Chem 1996;271:30340-6.
19. Kornilova ES, Sorkin AD, Nikolskiy NN. Compartmentalization dynamics of the epidermal growth factor in A431 cells. Tsitologiia 1987;29:904-10.
20. Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A99-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 2005;11:7080s-6s.
21. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-8.
22. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999;4:1029-40.
23. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002;156:843-54.
24. Merion M, Sly WS. The role of intermediate vesicles in the adsorptive endocytosis and transport of ligand to lysosomes by human fibroblasts. J Cell Biol 1983;96:644-50.
25. Nesterov A, Lysan S, Vdovina I, Nikolsky N, Fujita DJ. Phosphorylation of the epidermal growth factor receptor during internalization in A-431 cells. Arch Biochem Biophys 1994;313:351-9.
26. Normanno N, Campiglio M, Maiello MR, De Luca, Mancino M, Gallo M et al. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat 2008;112:25-33
27. Okabayashi Y, Kido Y, Okutani T, Sugimoto Y, Sakaguchi K, Kasuga M. Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. J Biol Chem 1994;269:18674-8.
28. Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992;9:383-91.
29. Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S et al. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 2009;77(5):781-93.
30. Sorkin A, Kornilova E, Teslenko L, Sorokin A, Nikolsky N. Recycling of epidermal growth factor-receptor complexes in A431 cells. Biochim Biophys Acta 1989;1011:88-96.
31. Takaoka S, Iwase M, Uchida M, Yoshiba S, Kondo G, Watanabe H et al. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells. Int J Oncol 2007;30:1469-76.
32. Wang Y, Pennock S, Chen X, Wang Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 2002;22:7279-90.